The U.S. Food and Drug Administration granted the breakthrough therapy designation to a medicine known as erdafitinib.
Erdafitinib was discovered by Johnson & Johnson's Janssen Pharmaceutical Cos. and privately held Astex Pharmaceuticals, Inc. as part of a partnership. It is being studied to treat urothelial cancer, which is most frequently in the bladder and the sixth most common type of cancer in the U.S.
The designation was granted based on data from a phase 2 clinical trial and will help to expedite developing the treatment.
